On-Q-ity is a next-generation diagnostics company transforming cancer treatment through non-invasive diagnostic monitoring. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the efficacy of treatment. On-Q-ity was formed through the merger of Cellective DX, a developer of microfluidics devices to capture and analyze circulating tumor cells from the blood of cancer patients, with The DNA Repair Company, a molecular diagnostics company developing biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors.

The company's CTC and biomarker technologies originated from groundbreaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively.  Headquartered in Waltham, MA, On-Q-ity is funded by Atlas Venture, Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Physic Ventures and Northgate Capital. For more information: www.On-Q-ity.com.